 Home > Medical News > Medicines Company News > Mycophenolate sodium enteric-coated tablets, a subsidiary of Hengrui Pharmaceuticals, was approved for listing

Mycophenolate sodium enteric-coated tablets, a subsidiary of Hengrui Pharmaceuticals, was approved for listing

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

sodium hypochlorite hazards

sodium facts

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 6, Hengrui Medicine issued an announcement stating that its subsidiary Chengdu Shengdi had recently received the "Drug Registration Certificate" for mycophenolate sodium enteric-coated tablets approved and issued by the State Food and Drug Administration.

Mycophenolate Sodium is a hypoxanthine monophosphate dehydrogenase (IMPDH) inhibitor.

Mycophenolate sodium enteric-coated tablets were developed by Novartis under the trade name Myfortic.

Upon inquiry, the global sales of mycophenolic acid tablets in 2019 was approximately US$499.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.